Exemestane 25mg Tablets

Prescriber Criteria: Consultant Oncologist

Out-Patient and In-Patient Use:

1. Malignancy

To be used as a last resort after treatment with the non-steroidal aromatase inhibitors, anastrozole/letrozole, upon disease progression for the:

- Adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer, following 2-3 years of initial adjuvant tamoxifen therapy;
- Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following anti-oestrogen therapy.

Duration of Approval:

1 year